BioCentury
ARTICLE | Company News

Newco Cardeus in-licenses Astellas compounds

April 1, 2011 12:10 AM UTC

Astellas Pharma Inc. (Tokyo:4503) granted new company Cardeus Pharmaceuticals Inc. (Menlo Park, Calif.) exclusive, worldwide rights, excluding Japan, to three compounds for undisclosed indications. The compounds include: YM758, an undisclosed ion channel protein inhibitor; ASP6537, a selective cyclooxygenase-1 (COX-1) inhibitor; and a preclinical compound. Cardeus will be responsible for all development and commercialization. Astellas is eligible for an upfront payment, milestones and royalties. Astellas also has rights of first negotiation for Europe and the U.S. and right to first refusal in China. ...